Your email has been successfully added to our mailing list.

×
0 0 0 0 -0.094298245614035 -0.091374269005848 -0.0701754385964912 -0.0643274853801169
Stock impact report

Silence Therapeutics CEO Craig Tooman steps down [Seeking Alpha]

Silence Therapeutics Plc - American Depository Share (SLN) 
Company Research Source: Seeking Alpha
He had served in that role since 2022 and was also president. The company said the decision to leave was done by mutual consent. No other details were provided. Iain Ross, Silence's board chairman, will lead the company on an interim basis. James Ede Golightly, a former non-executive director, has been re-appointed to the board. More on Silence Therapeutics Silence Therapeutics: Divesiran Targets High-Burden PV Seeking Alpha's Quant Rating on Silence Therapeutics Historical earnings data for Silence Therapeutics Financial information for Silence Therapeutics Recommended For You More Trending News Show less Read more
Impact Snapshot
Event Time:
SLN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for SLN alerts
Opt-in for
SLN alerts

from News Quantified
Opt-in for
SLN alerts

from News Quantified